drugset / Trial / NCT07028125
Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
The aim of the study is to evaluate the impact of digital monitoring of self-reported symptoms (PROs) on the adjustment of treatment management in patients treated with cabozantinib plus nivolumab for advanced clear cell renal cell carcinoma (RCC) in real life during the first 3 months of combined treatment
Timeline
- Start
- 2025-10-01
- Primary completion
- 2028-10
- Completion
- 2029-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Cabozantinib | Small molecule | 40 mg | Oral |
| Background | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |